News

Keryx Biopharmaceuticals (Keryx) has provided updated efficacy and safety data as well as new survival data on the clinical activity of KRX-0401 (perifosine) in combination with Bortezomib (Velcade)

Johnson & Johnson Pharmaceutical Research and Development (Johnson & Johnson) has reported results from the Phase III Einstein-Extension (EXT) clinical trial of the oral anticoagulant Rivaroxaban, which showed

Pharmacyclics has reported interim results from a Phase I/II study showing safety and clinical activity in patients with relapsed / recurrent non-hodgkin’s lymphoma (NHL) treated with its HDAC

ImmunoGen has reported positive clinical data with IMGN901 candidate in the treatment of relapsed and relapsed/refractory multiple myeloma (MM), including prolonged benefit in patients whose disease had progressed

Onyx Pharmaceuticals (Onyx) has reported updated safety data from the pivotal Phase 2b 003-A1 study, known as the 003 trial, demonstrating that Carfilzomib is well-tolerated in heavily pre-treated

Aspen Technology (Aspen) has released its aspenONE V7 software in nine new languages – Chinese, French, German, Italian, Japanese, Korean, Portuguese, Russian and Spanish. The company said that

Agilent Technologies has introduced GeneSpring GX 11, the latest generation of its desktop software for visualising and analysing microarray data, and GeneSpring Workgroup 11, the enterprise version of

Boehringer Ingelheim has reported results from the Recover study investigating Dabigatran Etexilate (150 mg BID), a direct thrombin inhibitor (DTI), compared to dose-adjusted Warfarin in patients with acute

Alexion PharmaceuticalsSoliris (eculizumab) developed by Alexion, a first-in-class terminal complement inhibitor, was found to reduce hemolysis and transfusion requirements, and improved measures of fatigue, when added to ongoing